Biolegend, 786702, Biotinylated Recombinant Human CTLA-4-Fc Chimera (carrier-free)

Name: Biotinylated Recombinant Human CTLA-4-Fc Chimera (carrier-free)
Brand: Biolegend
SKU: 786702

10microg

Catalog Number: 786702

Pricing

Send an RFQ.

View RFQ List

Category

Amino Acids

Description

Human cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a member of the IgG superfamily. It encodes a 223 amino acid protein and possesses a single extracellular V domain, a transmembrane domain, and a cytoplasmic domain. CTLA-4 is ~30% homologous with CD28, and both bind to the same ligands (B7-1/CD80 and B7-2/CD86) although CTLA-4 binds with higher affinity than CD28. Parallel recognition of a specific MHC-peptide complex by the T-cell receptor and of CD80 or CD86 by the costimulatory receptor CD28 results in T cell activation, cytokine production, proliferation, and differentiation. After the T cells' activation process and upregulation of CTLA-4, co-ligation of the TCR to the MHC-peptide complex and CTLA-4 to its ligands results in cell cycle arrest and ends T cell activation. It has been suggested that the negative regulatory mechanism of CTLA-4 is mediated through trans-endocytosis of CD80 and CD86 (capture of ligands from opposing cells). The ligands are removed from the original cell and degraded inside of CTLA-4-expressing cells. As a result, the action of CD28 is impaired. Alternative splice variants of CTLA-4 have been described in mice and humans that have transcripts that skip exon 2 (ligand-binding domain) or exon 3 (transmembrane domain). The ligand independent CTLA-4 is expressed in mice, but not in humans, and soluble CTLA-4 (sCTLA-4) is expressed in mice and humans. CTLA-4 is constitutively expressed by Tregs, and they are an important source of sCTLA-4. It has been suggested that sCTLA-4 potentiates regulatory T cell function. High levels of sCTLA-4 in Tregs have been associated with type 1 diabetes (T1D) and other autoimmune diseases, such as Grave's disease and myasthenia gravis. Also, CTLA-4 has been linked with proliferation and survival of chronic lymphocytic leukemia. CTLA-4 is a target for therapeutic intervention; in fact, a monoclonal antibody against CTLA-4 (Ipilimumab) has been approved for the treatment of melanoma.

Specifications

General

Source	Human CTLA-4, amino acids Ala31-Phe162 (Accession # BC070162) with a C-terminal human IgG1 Fc tag was expressed in CHO cells.
Molecular Mass	The unlabeled 360 amino acid recombinant protein has a predicted molecular mass of approximately 39.9 kD. The DTT-reduced and non-reduced glycosylated protein migrate at approximately 56 kD and 105 kD respectively by SDS-PAGE. The N-terminal amino acid is Ala.
Purity	>95%, as determined by Coomassie stained SDS-PAGE.
Formulation	0.22 µm filtered protein solution is in PBS, pH 7.2, 5% glycerol.
Endotoxin Level	Less than 0.01 ng/µg cytokine as determined by the LAL method.
Concentration	10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling	Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year. For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 50 - 100 µg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 0.2 - 1% BSA or HSA and stored in working aliquots at -20°C to -70°C. Avoid repeated freeze/thaw cycles.

Ordering

Notice

Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:

[email protected]

Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.

Biolegend, 786702, Biotinylated Recombinant Human CTLA-4-Fc Chimera (carrier-free)

Send an RFQ.

General

Notice

More from Biolegend.

Zombie Aqua™ Fixable Viability Kit

FITC anti-human CD3 Antibody

FITC anti-human CD3 Antibody

PE/Cyanine7 anti-human CD154

More from Biolegend.

Zombie Aqua™ Fixable Viability Kit

FITC anti-human CD3 Antibody

FITC anti-human CD3 Antibody

PE/Cyanine7 anti-human CD154